1. REVOLADE Summary of Product Characteristics. February 2019. 2. Bussel JB, Mahmud SN, Brigstocke SL, Torneten SM. Tapering eltrombopag in patients with chronic ITP: how successful is this and in whom does it work? Blood. 2015;126(23):1054. 3. González-López TJ, Pascual C, Álvarez-Román MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E40-E43. 4. Taylor A, Westwood JP, Laskou F, McGuckin S, Scully M. Thrombopoietin receptor agonist therapy in thrombocytopenia: ITP and beyond. Br J Haematol. 2017;177(3):475-480. 5. Lucchini E, Palandri F, Volpetti S, et al. Eltrombopag as second line therapy in adult patients with primary immune thrombocytopenia (ITP) in attempt to achieve long-term remission. Preliminary analysis of a phase II, multicenter, prospective study by GIMEMA Group (the ESTIT Study). Presented at: 60th Annual American Society of Hematology Meeting and Exposition; December 1, 2018; San Diego, CA.